Israel-Medical-Healthcare

[midastouch017]

Kamada to develop emphysema drug for Pari inhaler

Kamada will receive an exclusive user license for Pari’s inhalers and technology to develop inhaler-delivered API.

Gali Weinreb 18 Jan 06 17:26

Kamada Ltd. (TASE:KMDA), a maker of generic human plasma therapeutics, has signed an agreement with Pari Respirator Equipment of Germany, under which Kamada will develop and conduct clinical trials of its API drug for inhalers for the treatment of pulmonary emphysema.
The inhalers are a strategic product for the company, protected with orphan drug status in Europe, and, if they reach market, will be sold as an exclusive product in their field. All current treatments for pulmonary emphysema are by injection. Kamada is also a leading producer of drugs for injection treatments for the disease.

Pari is one of the world’s leaders in inhalers. Under the MOU between the two companies, Kamada will receive an exclusive user license for Pari’s inhalers and technology to develop inhaler-delivered API. The agreement will allow Kamada to conduct pre-clinical and clinical trials and to register API while using Pari’s inhalers. Pari will provide inhalers and technical support at its expense for the clinical trials, until the product is registered. Kamada will pay Pari royalties from product sales.

Published by Globes [online], Israel business news - www.globes.co.il - on January 18, 2006

Dubi